Literature DB >> 1683047

A unified serotyping scheme for Moraxella bovis.

L J Moore1, A W Lepper.   

Abstract

Fifty-three Australian, seven British, two American and two New Zealand isolates of Moraxella bovis were classified into seven serogroups on the basis of their variable fimbrial (pilus) antigens using whole cell slide agglutination (SA), enzyme-linked immunosorbent assays (ELISA) and tandem-crossed immunoelectrophoresis (TCIE). Although results of serogroup classification by SA and ELISA were identical in 68.7% of isolates, it was found necessary to resolve the discrepancies between the two systems using TCIE. Results suggest that world-wide variation in the potentially host-protective fimbrial antigens of M. bovis may be relatively limited. It is proposed that the previous numerical classifications of British and Australian serogroups are appropriately amalgamated as a result of this latest study and are designated as serogroups A to G inclusive. A protocol for the further serotyping of fresh, fimbriate isolates of M. bovis is suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683047     DOI: 10.1016/0378-1135(91)90111-r

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  10 in total

1.  Molecular characterization of a secreted enzyme with phospholipase B activity from Moraxella bovis.

Authors:  J L Farn; R A Strugnell; P A Hoyne; W P Michalski; J M Tennent
Journal:  J Bacteriol       Date:  2001-11       Impact factor: 3.490

Review 2.  Type IV pilin proteins: versatile molecular modules.

Authors:  Carmen L Giltner; Ylan Nguyen; Lori L Burrows
Journal:  Microbiol Mol Biol Rev       Date:  2012-12       Impact factor: 11.056

3.  Ocular immune responses in steers following intranasal vaccination with recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid.

Authors:  John A Angelos; Judy M Edman; Munashe Chigerwe
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

4.  Characterization of pilin genes from seven serologically defined prototype strains of Moraxella bovis.

Authors:  J L Atwell; J M Tennent; A W Lepper; T C Elleman
Journal:  J Bacteriol       Date:  1994-08       Impact factor: 3.490

5.  Characterization of hemolysin of Moraxella bovis using a hemolysis-neutralizing monoclonal antibody.

Authors:  F M Billson; C Harbour; W P Michalski; J M Tennent; J R Egerton; J L Hodgson
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Whole genome sequencing of Moraxella bovis strains from North America reveals two genotypes with different genetic determinants.

Authors:  Emily L Wynn; Matthew M Hille; John Dustin Loy; Gennie Schuller; Kristen L Kuhn; Aaron M Dickey; James L Bono; Michael L Clawson
Journal:  BMC Microbiol       Date:  2022-10-21       Impact factor: 4.465

7.  Relatedness of type IV pilin PilA amongst geographically diverse Moraxella bovoculi isolated from cattle with infectious bovine keratoconjunctivitis.

Authors:  John A Angelos; Kristin A Clothier; Regina L Agulto; Boguslav Mandzyuk; Morten Tryland
Journal:  J Med Microbiol       Date:  2021-02       Impact factor: 2.472

8.  Large genomic differences between Moraxella bovoculi isolates acquired from the eyes of cattle with infectious bovine keratoconjunctivitis versus the deep nasopharynx of asymptomatic cattle.

Authors:  Aaron M Dickey; John D Loy; James L Bono; Timothy P L Smith; Mike D Apley; Brian V Lubbers; Keith D DeDonder; Sarah F Capik; Robert L Larson; Brad J White; Jochen Blom; Carol G Chitko-McKown; Michael L Clawson
Journal:  Vet Res       Date:  2016-02-13       Impact factor: 3.683

9.  Whole genome sequencing of Moraxella bovoculi reveals high genetic diversity and evidence for interspecies recombination at multiple loci.

Authors:  Aaron M Dickey; Gennie Schuller; J Dustin Loy; Michael L Clawson
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

10.  A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis.

Authors:  Matthew M Hille; Matthew L Spangler; Michael L Clawson; Kelly D Heath; Hiep L X Vu; Rachel E S Rogers; John Dustin Loy
Journal:  Vaccines (Basel)       Date:  2022-06-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.